Nabihah Tayob

5.3k total citations · 3 hit papers
130 papers, 3.0k citations indexed

About

Nabihah Tayob is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nabihah Tayob has authored 130 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 42 papers in Cancer Research and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nabihah Tayob's work include Breast Cancer Treatment Studies (25 papers), HER2/EGFR in Cancer Research (25 papers) and Advanced Breast Cancer Therapies (22 papers). Nabihah Tayob is often cited by papers focused on Breast Cancer Treatment Studies (25 papers), HER2/EGFR in Cancer Research (25 papers) and Advanced Breast Cancer Therapies (22 papers). Nabihah Tayob collaborates with scholars based in United States, Italy and Brazil. Nabihah Tayob's co-authors include Susan Murray, Amit G. Singal, Fernando J. Martínez, Neehar D. Parikh, Ziding Feng, Kevin R. Flaherty, Hashem B. El‐Serag, Fasiha Kanwal, Eric S. White and Bethany B. Moore and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nabihah Tayob

119 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer

2022 147 citations Paolo Tarantino, Qingchun Jin et al. profile →
The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States

2022 131 citations Nabihah Tayob, Fasiha Kanwal et al. Clinical Gastroenterology and Hepatology profile →
Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?

2022 98 citations Neehar D. Parikh, Nabihah Tayob et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nabihah Tayob United States	27	1.0k	974	668	615	541	130	3.0k
Desmond Yip Australia	30	938 0.9×	1.6k 1.7×	262 0.4×	321 0.5×	398 0.7×	162	2.9k
Beatriz de Camargo Brazil	32	1.0k 1.0×	927 1.0×	248 0.4×	489 0.8×	345 0.6×	145	3.6k
Elena Garralda Spain	28	650 0.6×	1.7k 1.7×	281 0.4×	561 0.9×	551 1.0×	210	3.3k
Baruch Brenner Israel	34	816 0.8×	2.3k 2.4×	571 0.9×	212 0.3×	274 0.5×	158	3.8k
Christopher J. Johnson United States	25	425 0.4×	1.3k 1.4×	618 0.9×	177 0.3×	367 0.7×	41	2.7k
Colin Hessel United States	14	595 0.6×	596 0.6×	711 1.1×	146 0.2×	262 0.5×	25	2.1k
Howard J. Lim Canada	28	593 0.6×	1.1k 1.1×	205 0.3×	233 0.4×	438 0.8×	184	2.3k
Erika Martinelli Italy	23	859 0.8×	2.2k 2.2×	214 0.3×	497 0.8×	577 1.1×	86	3.4k
Smitha Krishnamurthi United States	25	939 0.9×	2.2k 2.2×	213 0.3×	227 0.4×	547 1.0×	126	3.3k
Jean‐Pierre Lotz France	26	699 0.7×	1.6k 1.7×	199 0.3×	226 0.4×	447 0.8×	119	2.8k

Countries citing papers authored by Nabihah Tayob

Since Specialization

Citations

This map shows the geographic impact of Nabihah Tayob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nabihah Tayob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nabihah Tayob more than expected).

Fields of papers citing papers by Nabihah Tayob

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nabihah Tayob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nabihah Tayob. The network helps show where Nabihah Tayob may publish in the future.

Co-authorship network of co-authors of Nabihah Tayob

This figure shows the co-authorship network connecting the top 25 collaborators of Nabihah Tayob. A scholar is included among the top collaborators of Nabihah Tayob based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nabihah Tayob. Nabihah Tayob is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Corti, Chiara, Xun Chu, Pedro Exman, et al.. (2025). Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study. ESMO Open. 10(8). 105521–105521.

Singal, Amit G., Neehar D. Parikh, Fasiha Kanwal, et al.. (2024). National Liver Cancer Screening Trial (TRACER) study protocol. Hepatology Communications. 8(11). 7 indexed citations

Zañudo, Jorge Gómez Tejeda, Romualdo Barroso‐Sousa, Esha Jain, et al.. (2024). Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature Communications. 15(1). 2446–2446. 15 indexed citations

El‐Serag, Hashem B., Qingchun Jin, Nabihah Tayob, et al.. (2024). HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 81(2). 465–475. 15 indexed citations

Leone, José Pablo, Julieta Leone, Michael J. Hassett, et al.. (2024). Incidence, treatment patterns, and mortality for patients with breast cancer during the first year of the COVID-19 pandemic: a population-based study. Breast Cancer Research and Treatment. 210(2). 285–294. 2 indexed citations

Grinshpun, Albert, Shan Ren, Noah Graham, et al.. (2024). Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer. ESMO Open. 9(6). 103465–103465. 4 indexed citations

Daher, Darine, Nicole E. Rich, Nabihah Tayob, et al.. (2024). Hepatocellular Carcinoma Screening in a Contemporary Cohort of At-Risk Patients. JAMA Network Open. 7(4). e248755–e248755. 12 indexed citations

Garrido-Castro, Ana C., Se Eun Kim, Rita Nanda, et al.. (2024). SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.. Journal of Clinical Oncology. 42(17_suppl). LBA1004–LBA1004. 20 indexed citations

Sandoval, Renata Lazari, Michele Bottosso, Tianyu Li, et al.. (2024). TP53-associated early breast cancer: new observations from a large cohort. JNCI Journal of the National Cancer Institute. 116(8). 1246–1254. 6 indexed citations

10.

Weiss, Anna, Qingchun Jin, Adrienne G. Waks, et al.. (2023). Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial. Journal of the American College of Surgeons. 238(3). 303–311. 2 indexed citations

11.

Trapani, Dario, Qingchun Jin, Caroline Block, et al.. (2023). Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor–Positive Breast Cancer: Implications for Guidance and Reimbursement. JCO Oncology Practice. 19(8). 560–570. 1 indexed citations

12.

Leone, Julieta, Michael J. Hassett, Rachel A. Freedman, et al.. (2023). Abstract PD6-08: PD6-08 Mortality risks over 20 years in men with stage I-III hormone receptor-positive breast cancer. Cancer Research. 83(5_Supplement). PD6–8. 2 indexed citations

13.

Collins, Laura C., Yue Zheng, Nabihah Tayob, et al.. (2023). Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2- breast cancer (BC).. Journal of Clinical Oncology. 41(16_suppl). 505–505. 1 indexed citations

14.

Sella, Tal, Yue Zheng, Nabihah Tayob, et al.. (2022). Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). npj Breast Cancer. 8(1). 127–127. 5 indexed citations

15.

Parikh, Neehar D., Nabihah Tayob, & Amit G. Singal. (2022). Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?. Journal of Hepatology. 78(1). 207–216. 98 indexed citations breakdown →

16.

Parsons, Heather A., Erin Macrae, Hao Guo, et al.. (2021). Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. JCO Precision Oncology. 5(5). 896–903. 13 indexed citations

17.

Vaz-Luís, Inês, Tianyu Li, Nabihah Tayob, et al.. (2021). A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Research and Treatment. 189(2). 411–423. 4 indexed citations

18.

Tayob, Nabihah, Israel C. Christie, Peter Richardson, et al.. (2018). Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clinical Gastroenterology and Hepatology. 17(9). 1886–1893.e5. 40 indexed citations

19.

Salisbury, Margaret L., Meng Xia, Yueren Zhou, et al.. (2015). Idiopathic Pulmonary Fibrosis. CHEST Journal. 149(2). 491–498. 69 indexed citations

20.

Han, MeiLan K., Nabihah Tayob, Susan Murray, et al.. (2014). Predictors of Chronic Obstructive Pulmonary Disease Exacerbation Reduction in Response to Daily Azithromycin Therapy. American Journal of Respiratory and Critical Care Medicine. 189(12). 1503–1508. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact